Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Beta-DNA polymerase (pol β) is a small, essential eukaryotic enzyme primarily involved in the base excision repair (BER) pathway, which repairs damaged DNA bases and single-strand breaks. Pol β consists of an N-terminal dRP lyase domain and a C-terminal polymerase domain. It functions in gap-filling synthesis and removal of sugar-phosphate residues during BER. Inhibition of pol β can sensitize cells to chemotherapeutic agents that induce DNA damage, making it a potential therapeutic target, particularly in cancer.
Inhibition of DNA polymerase β lyase and/or polymerase activity, leading to impaired DNA repair and increased sensitivity to genotoxic drugs.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-DNA Polymerase (None).